Clinical Trial

Assessing Physical Function in Sickle Cell Patients Taking Voxelotor

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Voxelotor is a novel hemoglobin polymerization inhibitor which has been demonstrated to reduce hemolysis and improve hemoglobin levels. There have been numerous studies examining the clinical impact of voxelotor in sickle cell disease (SCD) patients, but there are few published reports on the effects of treatment on physical function in patients with SCD. The hypothesis to be tested is that anemic SCD patients will have improvements in performance after 6 months of voxelotor treatment.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2023-09-01; most recent amendment 2026-01-29.
Status change: Recruiting → Active, Not Recruiting 2025-01-15
Status change: Not Yet Recruiting → Recruiting 2023-10-24
Trial Details
NCT Number NCT06023199
Lead Sponsor Inova Health Care Services
Collaborators: Pfizer
Conditions Sickle Cell Disease
Enrollment 6 participants
Start Date 2023-10-23
Primary Completion 2025-09-17 (estimated)
Study Completion 2026-06-15 (estimated)
Updated on ClinicalTrials.gov 2026-02-02